Shimada Takashi
Kyowa Hakko Kirin Co., LTD. Biologics Research Laboratories, Japan.
Clin Calcium. 2013 Oct;23(10):1469-75.
In the last decade, Fibroblast growth factor (FGF) 23 has been shown to be a causative factor of hypophosphatemic rickets/osteomalacia, and considered as potential therapeutic target for this disease. Now the most attention is paid to FGF23 blockades as a new category of therapy that may replace the current supplementation of phosphate and active vitamin D. In this chapter, pharmacological actions of the FGF23-neutralizing antibodies in murine hypophosphatemic rickets/osteomalacia model are reviewed. In addition, other types of FGF23 blockades are also briefly discussed.
在过去十年中，成纤维细胞生长因子（FGF）23已被证明是低磷性佝偻病/骨软化症的致病因素，并被视为该疾病的潜在治疗靶点。目前，作为一种可能取代当前磷酸盐和活性维生素D补充疗法的新型治疗方法，FGF23阻断剂受到了最多关注。在本章中，我们综述了FGF23中和抗体在小鼠低磷性佝偻病/骨软化症模型中的药理作用。此外，还简要讨论了其他类型的FGF23阻断剂。
